Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 18/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487426 | 0.89 | FASN (0.51) | FASN | |
| SCHEMBL16486553 | 0.89 | FASN (0.62) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486572 | 0.89 | FASN (0.64) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486330 | 0.88 | FASN (0.50) | FASNKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL16486319 | 0.87 | FASN (0.62) | FASN | |
| SCHEMBL16513079 | 0.86 | FASN (0.64) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL22220990 | 0.86 | FASN (0.66) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486505 | 0.86 | FASN (0.64) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486321 | 0.86 | FASN (0.66) | FASNMAPTKDM4ENPC1ALDH1A1 | |
| SCHEMBL16486849 | 0.86 | FASN (0.64) | FASNMAPTKDM4ENPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | claimed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | claimed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | claimed |
| EP-3033339-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-22 | — | — | EP | claimed |
| WO-2015022038-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | claimed |
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2018-11-06 | — | — | US | disclosed |
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3033339-B1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-9790216-B2 | 3-substituted cyclopentylamine derivatives | MERCK PATENT GMBH (DE) | 2017-10-17 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-14 | — | — | US | disclosed |
| EP-3033339-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | Merck Patent GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022038-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022038-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022738-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | FASN 1/4885MAPT 4694/4885KDM4E 2000/4885 |
| US-10118919-B2 | 3-substituted cyclopentylamine derivatives | FASN, FADS1, ACOX3 | FASN 1/4885MAPT 4694/4885KDM4E 2000/4885 |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | FASN 2790/4885MAPT 118/4885KDM4E 3693/4885 |
| US-20160200714-A1 | 3-SUBSTITUTED CYCLOPENTYLAMINE DERIVATIVES | FASN, FADS1, ACOX3 | FASN 1/4885MAPT 4694/4885KDM4E 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.